Journal
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 148, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejps.2019.105082
Keywords
EMA guideline; Bioequivalence; Extended pharmaceutical equivalence; Generic topical products
Categories
Funding
- FCT [PEst-OE/QUI/UI0313/2014, POCI-01-0145-FEDER-007630]
- FCT (Fundacao para a Ciencia e Tecnologia. Portugal) [PD/BDE/135075/2017]
- Fundação para a Ciência e a Tecnologia [PD/BDE/135075/2017] Funding Source: FCT
Ask authors/readers for more resources
The approval of topical generic products is essentially governed by clinical endpoint studies. Is this the most efficient approach to document bioequivalence in these particular dosage forms? This issue has sparked multiple discussions among different stakeholders - academia, industry and several regulatory agencies - in the active pursuit for new and robust surrogate methodologies. This mini review attempts to critically discuss this topic in light of the recently issued European regulatory requirements within the proposed modular framework for bioequivalence assessment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available